Investigational lupus therapies: another one bites the dust, in this case Amgen's bispecific targeting ICOSL/BAFF (rozibafusp alfa/AMG 570 in a phase 2b study).

https://www.fiercebiotech.com/biotech/amgen-discontinues-rd-work-lupus-futility-reasons